Physician profile
Mark Edward Anderson
NPI 1386616639
$269.46
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $39.45 · 2021: $48.46 · 2022: $19.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $67.91 | 2020-2021 | |
| Abbvie INC. | $38.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.39 | 2019 | |
| Cook Medical LLC | $20.00 | 2021 | |
| Exeltis, USA INC. | $19.67 | 2022 | |
| Roche Diagnostics Corporation | $19.31 | 2019 | |
| Hologic Sales and Service, LLC | $19.26 | 2019 | |
| Duchesnay USA Incorporated | $15.88 | 2019 | |
| Novo Nordisk INC | $15.48 | 2019 | |
| Mission Pharmacal Company | $14.01 | 2019 | |
| Daiichi Sankyo INC. | $11.89 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.